Molecular imaging and related therapeutic options for medullary thyroid carcinoma: state of the art and future opportunities.
Fiche publication
Date publication
septembre 2023
Journal
Reviews in endocrine & metabolic disorders
Auteurs
Membres identifiés du Cancéropôle Est :
Pr IMPERIALE Alessio, Dr BURGY Mickaël
Tous les auteurs :
Imperiale A, Berti V, Burgy M, Cazzato RL, Piccardo A, Treglia G
Lien Pubmed
Résumé
Due to its rarity and non-specific clinical presentation, accurate diagnosis, and optimal therapeutic strategy of medullary thyroid carcinoma (MTC) remain challenging. Molecular imaging provides valuable tools for early disease detection, monitoring treatment response, and guiding personalized therapies. By enabling the visualization of molecular and cellular processes, these techniques contribute to a deeper understanding of disease mechanisms and the development of more effective clinical interventions. Different nuclear imaging techniques have been studied for assessing MTC, and among them, PET/CT utilizing multiple radiotracers has emerged as the most effective imaging method in clinical practice. This review aims to provide a comprehensive summary of the current use of advanced molecular imaging modalities, with a particular focus on PET/CT, for the management of patients with MTC. It aims to guide physicians towards a rationale for the use of molecular imaging also including theranostic approaches and novel therapeutical opportunities. Overall, we emphasize the evolving role of nuclear medicine in MTC. The integration of diagnostics and therapeutics by in vivo molecular imaging represents a major opportunity to personalize treatment for individual patients, with targeted radionuclide therapy being one representative example.
Mots clés
18F-DOPA, 18F-FDG, 68Ga-DOTA peptides, Medullary thyroid carcinoma, Molecular imaging, Nuclear medicine, PET, Theranostics
Référence
Rev Endocr Metab Disord. 2023 09 16;: